Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.

Trial Details

NCT ID
NCT07021066
Phase
PHASE1
Sponsor
SystImmune Inc.
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • BL-M05D1
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Aurora, Colorado, United States|39.72943,-104.83192
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • New Orleans, Louisiana, United States|29.95465,-90.07507

Key Eligibility Criteria

  • Signed the informed consent form voluntarily and agreed to follow the program requirements
  • Age: ≥18 years
  • Has a life expectancy of ≥3 months
  • Has documented locally advanced or metastatic solid tumor(s) that are known to potentially express CLDN18.2 as defined below that have recurred or …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →